ES2184903T3 - Derivados del acido barbiturico, procesos para su produccion y agentes farmaceuticos que contienen estos compuestos. - Google Patents

Derivados del acido barbiturico, procesos para su produccion y agentes farmaceuticos que contienen estos compuestos.

Info

Publication number
ES2184903T3
ES2184903T3 ES96944612T ES96944612T ES2184903T3 ES 2184903 T3 ES2184903 T3 ES 2184903T3 ES 96944612 T ES96944612 T ES 96944612T ES 96944612 T ES96944612 T ES 96944612T ES 2184903 T3 ES2184903 T3 ES 2184903T3
Authority
ES
Spain
Prior art keywords
correspond
compounds
several times
group
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96944612T
Other languages
English (en)
Spanish (es)
Inventor
Elmar Bosies
Angelika Esswein
Frank Grams
Hans-Willi Krell
Ernesto Menta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2184903T3 publication Critical patent/ES2184903T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/66—Thiobarbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES96944612T 1995-12-23 1996-12-20 Derivados del acido barbiturico, procesos para su produccion y agentes farmaceuticos que contienen estos compuestos. Expired - Lifetime ES2184903T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19548624A DE19548624A1 (de) 1995-12-23 1995-12-23 Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
ES2184903T3 true ES2184903T3 (es) 2003-04-16

Family

ID=7781338

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96944612T Expired - Lifetime ES2184903T3 (es) 1995-12-23 1996-12-20 Derivados del acido barbiturico, procesos para su produccion y agentes farmaceuticos que contienen estos compuestos.

Country Status (22)

Country Link
US (2) US6110924A (de)
EP (1) EP0869947B1 (de)
JP (1) JP4198752B2 (de)
KR (1) KR100440035B1 (de)
CN (1) CN1318406C (de)
AT (1) ATE226575T1 (de)
BR (1) BR9612232A (de)
CZ (1) CZ292503B6 (de)
DE (2) DE19548624A1 (de)
DK (1) DK0869947T3 (de)
ES (1) ES2184903T3 (de)
HU (1) HUP9901065A3 (de)
IL (1) IL125048A (de)
MX (1) MX9805063A (de)
NO (1) NO311572B1 (de)
NZ (1) NZ325802A (de)
PL (1) PL190217B1 (de)
PT (1) PT869947E (de)
RU (1) RU2177475C2 (de)
TW (1) TW518324B (de)
WO (1) WO1997023465A1 (de)
ZA (1) ZA9610765B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0989982B1 (de) 1997-06-21 2005-08-17 Roche Diagnostics GmbH Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
RU2188196C2 (ru) * 1998-05-26 2002-08-27 Ашкинази Римма Ильинична N-замещенные производные 5-оксииминобарбитуровой кислоты
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6265578B1 (en) 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
AP2001002319A0 (en) 2000-10-26 2001-12-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
US6716845B2 (en) * 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
CN100338041C (zh) * 2001-05-03 2007-09-19 霍夫曼-拉罗奇有限公司 明胶酶抑制剂与抗肿瘤剂的组合以及其应用
MXPA03009995A (es) 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
AU2002346729A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
WO2004110457A1 (en) * 2003-06-06 2004-12-23 F. Hoffmann-La Roche Ag Matrix metalloproteinases inhibitors for the stimulation and protection of bone marrow stem cells
CA2561660C (en) * 2004-04-01 2012-10-30 Universite De Liege Pharmaceutical compositions of pyrimidine-2,4,6-triones
WO2005097133A1 (en) * 2004-04-01 2005-10-20 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
EP1632489A1 (de) * 2004-08-24 2006-03-08 University of Liege 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione Derivate als Inhibitoren von Zink Metalloendopeptidasen, ihre Herstellung und Verwendung.
RU2412189C1 (ru) * 2009-07-14 2011-02-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) СПОСОБ ПОЛУЧЕНИЯ 5-(4-ОКСО-2-ТИОКСО-1,3,4,5-ТЕТРАГИДРО-2Н-ХРОМЕНО[2,3-d]ПИРИМИДИН-5-ИЛ)-2-ТИОКСОДИГИДРОПИРИМИДИН-4,6(1Н,5Н)-ДИОНА
CN102234249B (zh) * 2010-04-23 2013-08-28 首都医科大学 N-(六氢嘧啶-1,3-二基)-二-l-氨基酸甲酯及其制备方法和应用
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101822417B1 (ko) * 2017-06-14 2018-01-29 주식회사 청도제약 인간의 체액에서 산화 스트레스를 측정하기 위한 방법
KR102432016B1 (ko) 2020-07-31 2022-08-16 부산대학교 산학협력단 신경염증질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2078323A (en) * 1937-04-27 C-amino-substituted barbituric
US2084136A (en) * 1933-06-03 1937-06-15 Heyden Chem Fab Barbituric acid containing in the 5-position a pyridine group and method of preparing the same
DE763145C (de) * 1942-05-29 1954-05-03 Chem Fab Von Heyden A G Verfahren zur Herstellung von 5-AEthyl-5-piperidinobarbitursaeure
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
DE1246743B (de) * 1965-01-12 1967-08-10 Dresden Arzneimittel Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
AU1303697A (en) 1997-07-17
US6110924A (en) 2000-08-29
DE69624500T2 (de) 2003-07-17
CZ196898A3 (cs) 1998-09-16
CN1318406C (zh) 2007-05-30
JP2000505069A (ja) 2000-04-25
KR100440035B1 (ko) 2004-09-18
AU722513B2 (en) 2000-08-03
PT869947E (pt) 2003-03-31
IL125048A (en) 2004-02-19
ZA9610765B (en) 1998-07-17
DE69624500D1 (de) 2002-11-28
US6472396B1 (en) 2002-10-29
RU2177475C2 (ru) 2001-12-27
EP0869947A1 (de) 1998-10-14
PL190217B1 (pl) 2005-11-30
HUP9901065A2 (hu) 1999-09-28
JP4198752B2 (ja) 2008-12-17
IL125048A0 (en) 1999-01-26
CN1209123A (zh) 1999-02-24
HUP9901065A3 (en) 2001-10-29
MX9805063A (es) 1998-10-31
NO982901D0 (no) 1998-06-22
DK0869947T3 (da) 2003-02-24
DE19548624A1 (de) 1997-06-26
NO311572B1 (no) 2001-12-10
EP0869947B1 (de) 2002-10-23
WO1997023465A1 (en) 1997-07-03
NO982901L (no) 1998-08-24
CZ292503B6 (cs) 2003-10-15
PL327466A1 (en) 1998-12-07
KR19990076734A (ko) 1999-10-15
NZ325802A (en) 2000-05-26
ATE226575T1 (de) 2002-11-15
BR9612232A (pt) 1999-07-13
TW518324B (en) 2003-01-21

Similar Documents

Publication Publication Date Title
ES8704938A1 (es) Procedimiento para preparar nuevos derivados aminicos heteroaromaticos
ES2032899T3 (es) Agente cosmetico para aplicacion externa y su uso.
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
HN1993004031A (es) N - (4,6 dime) amin - 3 tri - 2 sulfo o una de sus sales utiles composicion herbicida que contiene el mismo y proceso para la produccion del compuesto.
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
ES8702787A1 (es) Procedimiento para preparar nuevos tetrahidro-benzotiazoles.
ES2050851T3 (es) Amidas de acido carboxilico y acido sulfonico.
CO5631438A2 (es) Profarmacos de aminoacidos excitadores
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
ES8400415A1 (es) "un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina".
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
DK0562512T3 (da) Sulfonamidocarbonylpyridin-2-carboxylsyreamider samt deres anvendelse som lægemidler
CO4700469A1 (es) 3-[4-(4(4-cianofenil)-1-piperazinanil)butil]-5]ciannoindol y su proceso de obtencion .
ES2149951T3 (es) Producto pseudodipeptido que posee un grupo imidazol y aplicaciones del mismo.
CO4950618A1 (es) Inhibidores de proteasas
ES2178205T3 (es) Compuestos amida indazol como agentes serotoninergicos.
ES479423A1 (es) Procedimiento para la preparacion de 2-2-tenoiltio-propio- nil-glicina.
ES2149036T3 (es) Sistema a base de derivado acido fosfonico y de metabisulfito para estabilizar el acido ascorbico.
ES8306750A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
PT94297A (pt) Processo para a preparacao de n-hetero-aril-purin-6-aminas e de composicoes farmaceuticas que as contem
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos
ES8801174A1 (es) Un procedimiento para la preparacion de derivados de tetrahidronaftaleno.
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
ES2160726T3 (es) Derivados de piperazin-2,5-diona como moduladores de resistencia a multiples farmacos.